Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 281-292 , June 2006

Pregnancy complications in PCOS

  • Roy Homburg (Professor of Reproductive Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +972 54 5999534; fax: +972 3 6427250.

References 

  1. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Human Reproduction Update. 1997;3:359–365
  2. Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. Human Reproduction (Oxford, England). 1996;11:2623–2628
  3. Macgregor AH, Johnson JE, Bunde CA. Further clinical experience with clomiphene citrate. Fertility and Sterility. 1968;19:616–622
  4. Creus M, Ordi J, Fabregues F, et al. The effect of different hormone therapies on integrin expression and pinopode formation in the human endometrium: a controlled study. Human Reproduction (Oxford, England). 2003;18:683–693
  5. Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clinical Endocrinology. 1990;33:271–278
  6. Hamilton-Fairley D, Kiddy D, Watson H, et al. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. British Journal of Obstetrics and Gynaecology. 1992;99:128–131
  7. Homburg R, Levy T, Berkovitz D, et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovary syndrome. Fertililty and Sterility. 1993;59:527–531
  8. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilisation are increased in women with polycystic ovaries and reduced by pituitary desensitisation with buserelin. Human Reproduction (Oxford, England). 1993;8:959–964
  9. Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Human Reproduction (Oxford, England). 2002;17:3220–3223
  10. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Human Reproduction (Oxford, England). 2001;16:2606–2609
  11. Hasegawa I, Tanaka K, Sanada H, et al. Studies on the cytogenetic and endocrinologic background of spontaneous abortion. Fertility and Sterility. 1996;65:52–54
  12. Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obesity Research. 2002;10:551–554
  13. Palomba S, Orio F, Falbo A, et al. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovarian syndrome. Fertility and Sterility. 2005;84:761–765
  14. Glueck CJ, Wang P, Fontaine RN, et al. Plasmonogen inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48:1589–1595
  15. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility and miscarriage. Lancet. 1990;336:1141–1144
  16. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome. British Medical Journal. 1988;297:1024–1026
  17. Sagle M, Bishop K, Alexander FM, et al. Recurrent early miscarriage and polycystic ovaries. British Medical Journal. 1988;297:1027–1028
  18. Watson H, Hamilton-Fairley D, Kiddy D, et al. Abnormalities of follicular phase luteinising hormone secretion in women with recurrent early miscarriage. Journal of Endocrinology. 1989;(supplement 123):[Abstract 25]
  19. Homburg R, Berkovitz D, Levy T, et al. In-vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertility and Sterility. 1993;60:858–863
  20. Armar NA, Lachelin GCL. Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with the polycystic ovary syndrome. British Journal of Obstetrics and Gynaecology. 1993;100:161–164
  21. Jakubowicz DJ, Seppala M, Jakubowicz S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vacularity and blood flow in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1126–1133
  22. Diamantis-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology. 2005;152:749–756
  23. Orio F, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. The Journal of Clinical Endocrinology and Metabolism. 2005;90:6072–6076
  24. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2002;87:569–574
  25. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2002;87:524–529
  26. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Human Reproduction (Oxford, England). 2002;17:2858–2864
  27. Palomba S, Orio F, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4801–4809
  28. Palomba S, Orio F, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4068–4074
  29. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Human Reproduction (Oxford, England). 2004;19:1230–1323
  30. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and Sterility. 2002;77:520–525
  31. Clark AM, Thornley B, Tomlinson L, et al. Weight loss results in significant improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction (Oxford, England). 1998;13:1502–1505
  32. Homburg R. Adverse effect of luteinizing hormone on fertility: fact or fantasy. Bailliere's Clinical Obstetrics and Gynaecology. 1996;12:555–563
  33. Van der Meer M, Hompes PGA, Scheele F, et al. The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with FSH in PCOS, a randomized study. Fertility and Sterility. 1996;66:571–575
  34. Homburg R, Eshel A, Kilborn J, et al. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Human Reproduction (Oxford, England). 1990;5:32–37
  35. Urman B, Sarac E, Dogan L, Gurgan T. Pregnancy in infertile PCOD patients. Complications and outcome. The Journal of Reproductive Medicine. 1997;42:501–505
  36. Bjercke S, Dale PO, Tanbo T, et al. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecologic and Obstetric Investigation. 2002;54:94–98
  37. Mikola M, Hiilesman V, Halttunen M, et al. Obstetric outcome in women with polycystic ovary syndrome. Human Reproduction (Oxford, England). 2001;16:226–229
  38. Weerakiet S, Srisombut C, Rojanasakul A, et al. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecological Endocrinology. 2004;19:134–140
  39. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstetrics and Gynecology. 1999;94:194–197
  40. Holte J, Gennarelli G, Wide L, et al. High prevalence of polycystic ovaries and associated clinical, endocrine and metabolic features in women with previous gestational diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism. 1998;83:1143–1150
  41. Kousta E, Cela E, Lawrence N, et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clinical Endocrinology. 2000;53:501–507
  42. Koivunen RM, Juutinen J, Vauhkonen I, et al. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2591–2599
  43. Anttila L, Karjala K, Pentilla RA, et al. Polycystic ovaries in women with geatational diabetes. Obstetrics and Gynecology. 1998;92:13–16
  44. Turhan NO, Seckin NC, Aybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. International Journal of Gynaecology and Obstetrics. 2003;81:163–168
  45. Haakova L, Cibula D, Rezabek K, et al. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Human Reproduction (Oxford, England). 2003;18:1438–1441
  46. Kashyap S, Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension. The Journal of Reproductive Medicine. 2000;45:991–994
  47. Diamant YZ, Rimon E, Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. European Journal of Obstetrics Gynecology and Reproductive Biology. 1982;14:199–204
  48. Fridstrom M, Nisell H, Sjoblom P, Hillensjo T. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia. Hypertens Pregnancy. 1999;18:73–80
  49. Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3558–3562
  50. Benitez R, Sir-Petermann T, Palomino A, et al. Prevalence of metaboli c disorders among family members of patients with polycystic ovary syndrome. Revista Medica de Chile. 2001;129:707–712
  51. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. International Journal of Obesity and Related Metabolic Disorders. 2003;27:710–715
  52. Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Human Reproduction (Oxford, England). 2005;20:2122–2126
  53. Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birth weight with diabetes and vascular diseases. Lancet. 1999;353:1789–1792
  54. Barker DPJ, Osmond C. Infant mortality, chidhood nutrition and ischaemic heart disease in England and Wales. Lancet. 1986;i:1077–1081

PII: S1521-690X(06)00030-3

doi: 10.1016/j.beem.2006.03.009

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 281-292 , June 2006

Article Tools